Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma Meeting Abstract
| Authors: | Ku, G. Y.; Wu, A. J. C.; Trivedi, N.; Maron, S. B.; Joshi, S. S.; Ilson, D. H.; Janjigian, Y. Y.; Shcherba, M.; Li, J.; Tang, L. H.; Yeh, R.; Sihag, S.; Park, B. J.; Jones, D. R.; Molena, D. |
| Abstract Title: | Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500554 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.355 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 355 -- Source: Wos |
